Navigation Links
VLST Corporation Announces In-licensing Agreement with Pfizer for Anti-CD40 Monoclonal Antibody
Date:8/31/2012

SEATTLE, Aug. 31, 2012 /PRNewswire/ -- VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for cancer and autoimmune and inflammatory disorders, today announced an in-licensing agreement with Pfizer Inc. for an anti-CD40 monoclonal antibody.

(Logo: http://photos.prnewswire.com/prnh/20120831/SF65959LOGO)

CP-870,893 is a potent CD40 agonist that has been evaluated in a number of preclinical and clinical trials to date. These studies have determined the safety profile, pharmacokinetics and pharmacodynamic parameters of CD40-mediated immune activation as well as the maximum tolerated dose of the antibody.  VLST plans to advance this compound into efficacy studies in an oncology setting.  VLST is currently evaluating multiple clinical opportunities.  Under the terms of the agreement, Pfizer will retain co-exclusive rights to CP-870,893 in the oncology vaccine field.

"We are excited to in-license this promising compound. With the transfer of the IND from Pfizer, we will accelerate the development of our clinical strategy and expand our focus in immunotherapy to include oncology," said Martin Simonetti, President and Chief Executive Officer of VLST.  "Our recent financing will help support our Phase 2 clinical efforts."

"This agreement with VLST is yet another example of how Pfizer is executing against its portfolio management goals in oncology while finding a positive way forward for those compounds leaving our pipeline," said Garry Nicholson, President and General Manager of Pfizer Oncology.  "VLST's expertise in immunotherapy makes the company a strong partner to continue the development of this compound and potentially deliver a new therapy to patients with cancer."

VLST completed a tranche of the Series B financing of $5 million in June 2012. The financing was led by ARCH Venture Partners and included OVP Venture Partners, WRF Capital and Versant Ventures.

About VLST
VLST Corporation is a privately held biotechnology company dedicated to the streamlined discovery and development of novel therapeutics for the treatment of cancer and inflammatory and autoimmune disorders. The VLST approach combines novel bioinformatics and cutting-edge proteomics to provide a rapid and rational approach to identifying new targets for the development of novel biologic therapies.  The VLST discovery platform has primary applications for the treatment of cancer and inflammatory and autoimmune diseases.  For more information, please visit www.vlstcorp.com.

Contact:
Julie Rathbun
Rathbun Communications, Inc.
julie@rathbuncomm.com
(206) 769-9219


'/>"/>
SOURCE VLST Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MGC Diagnostics Corporation Completes Sale of New Leaf Business Assets to Life Time - The Healthy Way of Life Company
2. MGC Diagnostics Corporation Reports Third Quarter Fiscal Year 2012 Operating Results
3. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
4. The Hygenic Corporations Custom Rubber Solutions Solve Industry Problems
5. MGC Diagnostics Corporation to Report Third Quarter Fiscal 2012 Financial Results on Thursday, August 30, 2012
6. Kewaunee Scientific Corporation Declares Quarterly Dividend
7. Siemens Healthcare Enters into Definitive Agreement to Acquire Penrith Corporation
8. MGC Diagnostics Corporation Launches New Corporate Website and Unveils New Logo
9. Comprehensive Care Corporation Names Jairo Estrada Senior Management Advisor To Assist in Growing the Companys New Pharmacy Initiatives
10. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Masimo Corporation in Connection with Executive Compensation
11. SpineMark Corporation Partners with PhDx and Millennium Environmental to Create an ISO type Spine Protocol Management System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2017)... Sept. 1, 2017  Explorers Like Us ( https://explorerslikeus.com/ ) ... aural experiences — and deliver these experiences as part of ... people feel and heal better. ... While nothing beats a walk, jog or ... mind, Life Environments™ is the next best thing when getting ...
(Date:8/29/2017)... HAMPTON, Va. , Aug. 29, 2017 ivWatch, LLC, ... of peripheral IV infiltrations, announced it has been awarded an Innovative ... improvement company in the country. ... A continuous monitoring device to aid in the early detection of ... The ...
(Date:8/28/2017)... ®, a division of LightScalpel ®, LLC, is announcing its new ... years of American veterinary laser surgery innovation, Aesculight® is revolutionizing veterinary laser ... ... his new VetScalpel laser. Dr. Duclos practices veterinary dermatology at the Animal ... ...
Breaking Medicine Technology:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... asked at a gathering of executive marketers this week about the value of ... , "Everything that has happened in business has brought us to the ...
(Date:9/20/2017)... ... September 20, 2017 , ... “They Sang At Her Funeral”: a tale of ... revealing the skeletons in their closets. “They Sang At Her Funeral” is the creation ... young and married with five children and twelve grandchildren. Before becoming a writer, Annalise ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a leading ... Denise Flannery, to its strategic advisory and client development team. , In ... with clients across different industries to develop and implement market-justified strategies, modernize and ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... McFarland has joined its executive team as the President of its HealthBI ... care management systems and contact centers. , “Scott is a utility player ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, has ... filter. When we’re born, Nature gives us a full supply of melanin – ... we continuously lose this natural glare-reducing pigment; however, around the age of thirty, we ...
Breaking Medicine News(10 mins):